Parvo preventative picks up speedDecember 29, 2020Elanco Animal Health is set to acquire the global rights to Kindred Biosciences’ proprietary KIND-030, a monoclonal antibody being developed for the treatment and prevention of canine parvovirus.
SPONSORED CONTENTAre Your Patients Fully Protected?Fleas, ticks, heartworms, and intestinal parasites—dogs face multiple threats. See how a multi-parasite approach can offer your patients a broad range of protection. + Learn More